LINCS Pilot Phase 1 Metadata Standards: Cell Lines
Abbreviation: LINCS 1: Cell Lines
This record is replaced by:
Developed in United States
Created in 2012
Scope and data types
How to cite this record FAIRsharing.org: LINCS 1: Cell Lines; LINCS Pilot Phase 1 Metadata Standards: Cell Lines; DOI: https://doi.org/10.25504/FAIRsharing.c2c96p; Last edited: Feb. 22, 2018, 2:14 p.m.; Last accessed: Nov 14 2018 1:44 p.m.
Record added: May 18, 2016, 10:14 a.m.
Record updated: Oct. 22, 2016, 8:05 p.m. by The FAIRsharing Team.
Edits to 'https://fairsharing.org/FAIRsharing.c2c96p' by 'The FAIRsharing Team' at 20:05, 22 Oct 2016 (approved): 'contactEmail' has been modified: Before: After: firstname.lastname@example.org
Edits to 'https://fairsharing.org/FAIRsharing.c2c96p' by 'The FAIRsharing Team' at 20:00, 22 Oct 2016 (approved): 'homepage' has been modified: Before: http://www.lincsproject.org/data/data-standards/ After: http://www.lincsproject.org/LINCS/data/previous-standards Support links have changed: Previous values: http://www.lincsproject.org/contact/ http://www.lincsproject.org/Files/Data%20Standards%20Resources/LINCS_DWG_CellLine_MetaData_Release_Apr-11-2012.pdf New values: http://www.lincsproject.org/LINCS/files/LINCS_DWG_CellLine_Metadata_Release_Apr-11-2012.pdf
No semantic standards defined
Models and Formats
No syntax standards defined
No identifier schema standards defined
The LINCS Data Portal provides a unified interface for searching LINCS dataset packages and reagents. LINCS data are being made openly available as a community resource through a series of data releases, so as to enable scientists to address a broad range of basic research questions and to facilitate the identification of biological targets for new disease therapies. LINCS datasets consist of assay results from cultured and primary human cells treated with bioactive small molecules, ligands such as growth factors and cytokines, or genetic perturbations. Many different assays are used to monitor cell responses, including assays measuring transcript and protein expression; cell phenotype data are captured by biochemical and imaging readouts. Assays are typically carried out on multiple cell types, and at multiple timepoints; perturbagen activity is monitored at multiple doses.
This record is not implemented by any policy.